Determining the β Decay Strength Function of 91Rb

The r-process predicts the formation of elements heavier than iron and occurs in neutron star mergers and supernovae. The β decay strength function reveals nuclear structure properties necessary to improve r-process models. Measurements of the 91Rb strength function, a nucleus involved in the r process, were made at the National Superconducting Cyclotron Laboratory (NSCL) this past July (2018). The 91Rb were made with the A1900 fragment recoil separator, then stopped in a long gas cell, and finally implanted in a mylar tape. Spectra and multiplicity of γ rays from the daughter, 91Sr, coincident with β particles from the decay of implanted 91Rb give one the information needed to determine the β decay strength function. Electrons produced by the β decay were measured in a plastic detector constructed at Hope College and γ rays were detected in the Summing NaI (SuN) detector. Coincidences between electrons and γ rays were needed to identify the energy level in the 91Sr daughter nucleus to which the parent 91Rb decayed and to quantify the probability of that decay path. β particles from the decay of 91Rb are difficult to distinguish from background events due to the buildup of long-lived daughter particles that subsequently also β decay. A tape system extending into the beam pipe through SuN is needed to move radioactive daughter particles away from the detector. Thus, a conventional Si surface barrier β detector could not be employed because of minimal space inside the beam pipe. The needed β detector was fabricated to fit inside the small beam pipe and around the tape system. The 20 cm long, barrel-shaped detector was constructed out of scintillating plastic with wave-shifting fiber optic cables on the exterior leading to photomultiplier tubes outside the SuN detector. Preliminary results are shown

Nucleosynthesis of Heavy Elements by Neutron Capture

Nucleosynthesis of elements heavier than the iron group by neutron capture on both slow and fast time scales is evaluated. The s-process calculations of Clayton, Fowler, Hull, and Zimmerman (1961) have been revised to include more recent experimental results on abundances and neutron capture cross- sections. The solar-system s-process abundances indicate a history of neutron exposure distributions characterized by decreasing probability of high integrated flux; an exponential exposure distribution is extracted. Estimates are made of the s-process contribution to each isotopic abundance; a table gives the amounts of elements produced by each process in the solar-system material. The r-process calculations are carried out using a semi-empirical atomic-mass law to determine neutron-binding energies and betadecay probabilities. The solar-system r-process material has probably been synthesized in two distinct types of environments, e.g., one of about 4 sec duration with temperature 2.4 X 10 K and neutron density 5 X tO , and the other of the same or longer duration with temperature 1.0 X 10 K and neutron density 3 X 1O both of these environments could be found in an object with mass 10 Mo

Boy Scouts of America Concept Site Master Plan and Improvements

Our team, G1 Engineering, has partnered with the Boy Scouts of America to provide an update to their master plan for the Outdoor Education Center site located at 600 S. 120th Street, Lincoln, NE. Our work included providing transportation solutions; drainage evaluations; investigation of geotechnical conditions; environmental evaluation and determination of permitting requirements; preparation of concept design plans for bridges, drainage, utilities, and overall site plan; and evaluation of structural elements included in the project. Two streams cross the property presenting site access issues. Our team provided pedestrian, UTV, and emergency vehicle access bridges to address these issues. With the two streams on the property, a majority of the land is classified as a floodway or a floodplain. As such, there are regulations placed on any structures built in these areas to not raise flood elevations. Recent expanded use of the facility has led to strains on the parking areas and wastewater facilities. Our team has proposed solutions for expanded parking lots and lagoon operations. Finally, our team investigated the geotechnical conditions present on the site to allow for proper construction and placement of foundations of proposed structures

Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand

Mononuclear phagocytes have been attributed a crucial role in the host defense toward influenza virus (IV), but their contribution to influenza-induced lung failure is incompletely understood. We demonstrate for the first time that lung-recruited “exudate” macrophages significantly contribute to alveolar epithelial cell (AEC) apoptosis by the release of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) in a murine model of influenza-induced pneumonia. Using CC-chemokine receptor 2–deficient (CCR2−/−) mice characterized by defective inflammatory macrophage recruitment, and blocking anti-CCR2 antibodies, we show that exudate macrophage accumulation in the lungs of influenza-infected mice is associated with pronounced AEC apoptosis and increased lung leakage and mortality. Among several proapoptotic mediators analyzed, TRAIL messenger RNA was found to be markedly up-regulated in alveolar exudate macrophages as compared with peripheral blood monocytes. Moreover, among the different alveolar-recruited leukocyte subsets, TRAIL protein was predominantly expressed on macrophages. Finally, abrogation of TRAIL signaling in exudate macrophages resulted in significantly reduced AEC apoptosis, attenuated lung leakage, and increased survival upon IV infection. Collectively, these findings demonstrate a key role for exudate macrophages in the induction of alveolar leakage and mortality in IV pneumonia. Epithelial cell apoptosis induced by TRAIL-expressing macrophages is identified as a major underlying mechanism

Muonium Decay

Modifications of the mu+ lifetime in matter due to muonium (M = mu+ e-) formation and other medium effects are examined. Muonium and free mu+ decay spectra are found to differ at O(alpha m_e/m_mu) from Doppler broadening and O(alpha^2 m_e/m_mu) from the Coulomb bound state potential. However, both types of corrections are shown to cancel in the total decay rate due to Lorentz and gauge invariance respectively, leaving a very small time dilation lifetime difference, (tau_M - tau_mu+)/tau_mu+ = alpha^2 m_e^2/ 2m_mu^2 \simeq 6\times 10^-10, as the dominant bound state effect. It is argued that other medium effects on the stopped mu+ lifetime are similarly suppressed.Comment: 14 pages, revte

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

Purpose. The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic response to neoadjuvant treatment in adult patients with primary bone sarcomas. Methods. Twelve consecutive patients with resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the initiation and after completion of neoadjuvant treatment. Imaging findings were correlated with histopathologic response. Results. Histopathologic responders showed significantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow up than non-responders (64 ± 19% versus 29 ± 30 %, resp.; P = .03). Using a 60% decrease in tumor FDG-uptake as a threshold for metabolic response correctly classified 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic responders and non-responders, respectively (sensitivity, 75%; specificity, 88%). Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients

A research agenda for curing chronic hepatitis B virus infection.

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142483/1/hep29509.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142483/2/hep29509_am.pd

Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays

BACKGROUND: Neuroblastomas are characterized by chromosomal alterations with biological and clinical significance. We analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity (LOH) and DNA copy number change using the Affymetrix 10K single nucleotide polymorphism (SNP) array. FINDINGS: Multiple areas of LOH and copy number gain were seen. The most commonly observed area of LOH was on chromosome arm 11q (15/22 samples; 68%). Chromosome 11q LOH was highly associated with occurrence of chromosome 3p LOH: 9 of the 15 samples with 11q LOH had concomitant 3p LOH (P = 0.016). Chromosome 1p LOH was seen in one-third of cases. LOH events on chromosomes 11q and 1p were generally accompanied by copy number loss, indicating hemizygous deletion within these regions. The one exception was on chromosome 11p, where LOH in all four cases was accompanied by normal copy number or diploidy, implying uniparental disomy. Gain of copy number was most frequently observed on chromosome arm 17q (21/22 samples; 95%) and was associated with allelic imbalance in six samples. Amplification of MYCN was also noted, and also amplification of a second gene, ALK, in a single case. CONCLUSIONS: This analysis demonstrates the power of SNP arrays for high-resolution determination of LOH and DNA copy number change in neuroblastoma, a tumor in which specific allelic changes drive clinical outcome and selection of therapy

A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State

OBJECTIVE: To examine the efficacy of ziprasidone vs. placebo for the depressive mixed state in patients with bipolar disorder type II or major depressive disorder (MDD). METHODS: 73 patients were randomized in a double-blinded, placebo-controlled study to ziprasidone (40-160 mg/d) or placebo for 6 weeks. They met DSM-IV criteria for a major depressive episode (MDE), while also meeting 2 or 3 (but not more nor less) DSM-IV manic criteria. They did not meet DSM-IV criteria for a mixed or manic episode. Baseline psychotropic drugs were continued unchanged. The primary endpoint measured was Montgomery-Åsberg Depression Rating Scale (MADRS) scores over time. The mean dose of ziprasidone was 129.7±45.3 mg/day and 126.1±47.1 mg/day for placebo. RESULTS: The primary outcome analysis indicated efficacy of ziprasidone versus placebo (p = 0.0038). Efficacy was more pronounced in type II bipolar disorder than in MDD (p = 0.036). Overall ziprasidone was well tolerated, without notable worsening of weight or extrapyramidal symptoms. CONCLUSIONS: There was a statistically significant benefit with ziprasidone versus placebo in this first RCT of any medication for the provisional diagnostic concept of the depressive mixed state. TRIAL REGISTRATION: Clinicaltrials.gov NCT00490542

Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap

Jennifer Polinski and colleagues estimated the effect of the "coverage gap" during which US Medicare beneficiaries are fully responsible for drug costs and found that the gap was associated with a doubling in discontinuing essential medications